Oncovin for Inj. 1mg（オンコビン注射用1mg） (六)
cal professionals with new treatment options as a result of this approval acquisition. We will continue to resolve unapproved drugs and non-indication drugs, and we will actively contribute to medical care.
Known applications * 1: Regarding application for approval of pharmaceutical products (adaptation addition etc.), the effectiveness and safety of the medicinal products are known in medicinal pharmacology and it is not necessary to submit an application for approval without newly implementing all or part of the clinical trial Institutions that can do
"Unconfirmed drugs with high medical necessity / non-approved drug review meeting" * 2: eva luate the medical need for drugs and indications that are approved for use in Europe and the US but are not approved in Japan As well as to promote the development of unapproved drugs and non-applicable drugs by pharmaceutical companies by confirming the suitability for public applications and the validity of the tests that need to be additionally carried out in order to apply for approval, etc. Meeting organized by Ministry of Health, Labor and Welfare established
|
